PODCAST: Aviation and the FAA: Unmanned Aircraft Systems — C&M’s First 100 Days Series
Client Alert | 1 min read | 12.14.16
As part of Crowell & Moring’s “First 100 Days” podcast series, Marc Warren, chair of the firm’s Aviation Group, and Steve Seiden, counsel in the group, sit down to discuss how the Trump Administration might affect the regulatory climate for commercial drones. Marc previously served as the deputy chief counsel of the Federal Aviation Administration, and Steve also served the FAA in various capacities, including a one-year assignment as special counsel to the agency’s chief counsel.
Discussed in this 18 minute podcast:
- Why Unmanned Aircraft Systems (UAS) are the next big thing, their potential, and industry and business applications.
- Current state of regulatory play – pilot requirements, when and where drones can be flown, and the waiver process.
- Opportunities and challenges for the Trump Administration.
- Near-term issues (a forthcoming notice of proposed rulemaking on microdrones).
- What’s next? (large drones, operations over people, and fully autonomous drones).
- Other issues worth tracking (Federal preemption, potential conflicts with state laws, and privacy issues).
Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
